Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the...
This year, the AACR Annual Meeting, the premier cancer research meeting in the world, is happening at the Georgia...
Immune-related adverse events (irAEs) is the collective term used to describe the side effects that arise in response to...
In 2018, we witnessed significant momentum in several hot areas of cancer research, including immunotherapy and precision medicine. Researchers...
One of the most watched areas in the immuno-oncology field is the development of chimeric antigen receptor (CAR) T-cell...
Pancreatic cancer remains a challenging disease to treat, with a five-year survival rate of less than 9 percent, according...
Last week saw a flurry of new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) for...